Searching for I-O surrogates

FDA’s development of an intermediate endpoint for immuno-oncology trials could provide a new surrogate that correlates better with overall survival than ORR or PFS as measured by RECIST criteria.

FDA has tested the new endpoint, called intermediate endpoint, or IME, using a data set from 5,806 patients in nine clinical trials of anti-PD-1 mAbs, all of which had OS as a primary or co-primary endpoint. ...